## UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 19, 2022

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

Kiniksa Pharmaceuticals, Ltd.

File No. 333-224488 - CF#35976

Kiniksa Pharmaceuticals, Ltd. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on April 27, 2018.

Based on representations by Kiniksa Pharmaceuticals, Ltd. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.7 through March 25, 2032

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Robert Errett Chief, Disclosure Management Office